Klotho Level as a Marker of Low Bone Mineral Density in Egyptian Sickle Cell Disease Patients.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
received:
08
10
2020
accepted:
06
05
2021
pubmed:
1
6
2021
medline:
17
2
2022
entrez:
31
5
2021
Statut:
ppublish
Résumé
Bone involvement of sickle cell disease (SCD) patients varies from acute clinical manifestations of painful vaso-occlusive crises or osteomyelitis to more chronic affection of bone mineral density (BMD) and debilitating osteonecrosis and osteoporosis. Secreted klotho protein is involved in calcium (Ca) reabsorption in the kidney. This study aimed to measure serum klotho levels in children with SCD to determine the possibility of using it as a marker of low BMD in children with SCD in correlation with a dual-energy radiograph absorptiometry scan. This study included 60 sickle disease patients and 30 age-matched and sex-matched control participants without SCD. A highly statistically significant difference was found between patients with normal BMD and those with low BMD, with serum Ca and klotho levels being lower in the latter group. Klotho serum level correlated positively with both serum Ca and BMD. Serum klotho level showed 94.9% sensitivity and 95.2% specificity in the detection of low BMD. Both serum Ca and klotho serum levels may be useful markers for detection of low BMD related to SCD with high sensitivity and specificity; however, klotho may be a better indicator as it is less affected by the nutritional and endocrinal status of patients or by intake of Ca supplements.
Identifiants
pubmed: 34054039
doi: 10.1097/MPH.0000000000002231
pii: 00043426-202201000-00012
doi:
Substances chimiques
Biomarkers
0
KL protein, human
EC 3.2.1.31
Klotho Proteins
EC 3.2.1.31
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e40-e45Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Conran N, Franco-Penteado CF, Costa FF. Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion. Hemoglobin. 2009;33:1–6.
Bennett OM, Namnyak SS. Bone and joint manifestations of sickle cell anaemia. J Bone Joint Surg Br. 1990;72:494–499.
Baldwin C, Nolan VG, Wyszynski DF, et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood. 2005;106:372–375.
Shiraki-Iida T, Aizawa H, Matsumura Y, et al. Structure of the mouse Klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett. 1998;424:6–10.
Kuro-o M. Klotho. Pflugers Arch. 2010;459:333–343.
Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118:3820–3828.
Shimada T, Hasegawa H, Yamazaki Y, et al. FGF‐23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435.
Imura A, Iwano A, Tohyama O, et al. Secreted Klotho protein in sera and CSF: implication for post‐translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 2004;565:143–147.
Imura A, Tsuji Y, Murata M, et al. α-Klotho as a regulator of calcium homeostasis. Science. 2007;316:1615–1618.
Alexander RT, Woudenberg-Vrenken TE, Buurman J, et al. Klotho prevents renal calcium loss. J Am Soc Nephrol. 2009;20:2371–2379.
Nijenhuis T, Hoenderop JG, Bindels RJ. TRPV5 and TRPV6 in Ca(2+) (re)absorption: regulating Ca(2+) entry at the gate. Pflugers Arch. 2005;451:181–192.
Lu P, Boros S, Chang Q, et al. The beta-glucuronidase klotho exclusively activates the epithelial Ca2+ channels TRPV5 and TRPV6. Nephrol Dial Transplant. 2008;23:3397–3402.
Tsuruoka S, Nishiki K, Ioka T, et al. Defect in parathyroid-hormone-induced luminal calcium absorption in connecting tubules of Klotho mice. Nephrol Dial Transplant. 2006;21:2762–2767.
Wildman SS, Henwood-Finley MJ. Pediatric DXA: a review of proper technique and correct interpretation. J Am Osteopath Coll Radiol. 2012;1:17–26.
Adebiyi AA, Oyebowale OM, Olaniyi AJ, et al. Heart rate variability study in adult Nigerian subjects with sickle cell disease during vaso-occlusive crisis. Niger Postgrad Med J. 2019;26:8.
Steinberg MH. Genetic etiologies for phenotypic diversity in sickle cell anemia. ScientificWorldJournal. 2009;9:46–67.
Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120:3647–3656.
Colino CG, Bieler CB, Díaz MP, et al. Evaluation of bone mineral density in children with sickle cell disease. An Pediatr (Barc). 2015;82:216–221.
Bordbar MR, Haghpanah S, Zarei T, et al. Evaluation of bone mineral density in children with sickle-cell anemia and its associated factors in the south of Iran: a case-control study. Arch Osteoporos. 2017;12:70.
Souza KC, Araújo PI, Souza-Junior PR, et al. Stunting and wasting in children and adolescents with sickle cell disease. Rev Nutr. 2011;24:853–862.
Rhodes M, Akohoue SA, Shankar SM, et al. Growth patterns in children with sickle cell anemia during puberty. Pediatr Blood Cancer. 2009;53:635–641.
Lukusa Kazadi A, Ngiyulu RM, Gini-Ehungu JL, et al. Factors associated with growth retardation in children suffering from sickle cell anemia: first report from central Africa. Anemia. 2017:7916348.
Shiba HF, El-Ghamrawy MK, Shaheen IA, et al. Glutathione S-transferase gene polymorphisms (GSTM1, GSTT1, and GSTP1) in Egyptian pediatric patients with sickle cell disease. Pediatr Dev Pathol. 2014;17:265–270.
Shaheen I, Khorshied M, Abdel-Raouf R, et al. L-selectin P213S and integrin alpha 2 C807T genetic polymorphisms in pediatric sickle cell disease patients. J Pediatr Hematol Oncol. 2020;42:e707–e711.
Ladu AI, Abba AM, Ogunfemi MK, et al. Prevalence of chronic complications among adults with sickle cell anaemia attending a tertiary hospital in North Eastern Nigeria. J Hematol Hemother. 2020;5:007.
Garadah TS, Hassan AB, Jaradat AA, et al. Predictors of abnormal bone mass density in adult patients with homozygous sickle-cell disease. Clin Med Insights Endocrinol Diabetes. 2015;8:35–40.
Mokhtar GM, Tantawy AA, Hamed AA, et al. Tartrate-resistant acid phosphatase 5b in young patients with sickle cell disease and trait siblings: relation to vasculopathy and bone mineral density. Clin Appl Thromb Hemost. 2017;23:64–71.
Adesina OO, Gurney JG, Kang G, et al. Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results. Blood Adv. 2019;3:1476–1488.
Sarrai M, Duroseau H, D ‘Augustine J, et al. Bone mass density in adults with sickle cell disease. Br J Haematol. 2007;136:666–672.
Sadat-Ali M, Al-Elq AH, Sultan O, et al. Low bone mass due to sickle cell anemia: is it becoming a real issue? West Afr J Med. 2008;27:218–223.
Ghaleb RM, Al Khoufi EA. Low bone mineral density in Saudi adult patients with sickle cell disease: myth or fact? Int J Clin Rheumatol. 2019;14:53.
Zheng S, Chen Y, Zheng Y, et al. Correlation of serum levels of fibroblast growth factor 23 and Klotho protein levels with bone mineral density in maintenance hemodialysis patients. Eur J Med Res. 2018;23:18.
Nabeshima Y. Regulation of calcium homeostasis by α-Klotho and FGF23. Clin Calcium. 2010;20:1677–1685.
Wolf MT, An SW, Nie M, et al. Klotho up-regulates renal calcium channel transient receptor potential vanilloid 5 (TRPV5) by intra- and extracellular N-glycosylation-dependent mechanisms. J Biol Chem. 2014;289:35849–35857.
Olauson H, Lindberg K, Amin R, et al. Parathyroid-specific deletion of klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet. 2013;9:e1003975.
Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun. 2001;280:1015–1020.
Maeda R, Imura A, Nabeshima Y. Complex regulation and diverse functions of alpha-Klotho. Contrib Nephrol. 2013;180:25–46.
Kurz DJ, Decary S, Hong Y, et al. Chronic oxidative stress compromises telomere integrity and accelerates the onset of senescence in human endothelial cells. J Cell Sci. 2004;117:2417–2426.
Ulug P, Vasavda N, Awogbade M, et al. Association of sickle avascular necrosis with bone morphogenic protein 6. Ann Hematol. 2009;88:803–805.
Ogata N, Matsumura Y, Shiraki M, et al. Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women. Bone. 2002;31:37–42.
Yamada Y, Ando F, Niino N, et al. Association of polymorphisms of the androgen receptor and klotho genes with bone mineral density in Japanese women. J Mol Med (Berl). 2005;83:50–57.
Riancho JA, Valero C, Hernández JL, et al. Association of the F352V variant of the Klotho gene with bone mineral density. Biogerontology. 2007;8:121–127.
Mullin BH, Wilson SG, Islam FM, et al. Klotho gene polymorphisms are associated with osteocalcin levels but not bone density of aged postmenopausal women. Calcif Tissue Int. 2005;77:145–151.
Zhang F, Zhai G, Kato BS, et al. Association between KLOTHO gene and hand osteoarthritis in a female Caucasian population. Osteoarthritis Cartilage. 2007;15:624–629.
Baldan A, Giusti A, Bosi C, et al. Klotho, a new marker for osteoporosis and muscle strength in β-thalassemia major. Blood Cells Mol Dis. 2015;55:396–401.
Chen CD, Tung TY, Liang J, et al. Identification of cleavage sites leading to the shed form of the anti-aging protein klotho. Biochemistry. 2014;53:5579–5587.